Nav: Home

New study underscores significant benefit of conversations between clinicians and patients

March 14, 2019

Across the United States, millions of individuals face serious, life-limiting illness like cancer, heart disease and stroke, respiratory disease and diabetes. The final year of life with serious illness can be filled with emotional distress and uncertainty about treatment options.

When people with serious illness have conversations with their doctors and nurses about their personal values, goals, and what might be ahead with their illness, they are more likely to receive the care they want, feel less distress and report better quality of life. However, only a third of patients in their last year of life report having these conversations and, often, they happen too late in the course of illness to fulfill their most important wishes. Experts agree that all patients with serious illness should have these conversations; we need a new approach to assure that all patients are able to reap these benefits.

A new study shows that an innovative communication program developed by Ariadne Labs and tested at the Dana-Farber Cancer Institute resulted in more, earlier and better conversations between patients and their oncology clinicians, and led to significant reductions in emotional suffering for patients with advanced cancer. On average, patients and clinicians had a serious illness conversation 2.4 months earlier -- almost five months before death. The conversations were centered on what matters most to patients, with 90 percent of patients discussing goals and values.

As a result of the intervention, the proportion of patients with moderate to severe anxiety and depression was reduced by half, and the anxiety improvements were sustained for at least 24 weeks. The study was unable to demonstrate whether the conversations resulted in care that aligned with patient goals, or brought about greater peacefulness at the end of life. The intervention did not impact survival rates.

The findings of the four-year randomized control trial of the Serious Illness Care Program were published in two papers, one in JAMA Internal Medicine and the other in JAMA Oncology on March 14. The study is the first to demonstrate meaningful improvement in patients' mental health symptoms from a structured communication intervention implemented by oncology clinicians, rather than palliative care or psychology specialists. In addition, the study shows that a multi-component intervention, using tools, training, and systems-change strategies can address the most common barriers to communication in a clinical setting and improve the quality, timing and occurrence of patient-centered conversations.

"We know how beneficial patient-centered conversations are, and our goal is to ensure that they happen for all patients, earlier in the course of illness and focus on what matters most to the patients," said study author Dr. Rachelle Bernacki, associate director of the Serious Illness Care program and a palliative care doctor at Dana-Farber Cancer Institute. "These results are exciting because they show us that more, better and earlier conversations are possible and they can reduce symptoms of depression and anxiety in our most vulnerable patients."

Achieving these results with clinicians outside the field of palliative medicine -- where such conversations typically happen -- is particularly important, said study co-author Dr. Joanna Paladino, who leads implementation of the Serious Illness Care Program at Ariadne Labs. "We have a dire shortage of palliative care clinicians in the United States and many patients who would benefit from patient-centered, safe and gentle serious illness conversations. What we found is that with communication skills training, a structured conversation guide and system-level support, we can equip many more clinicians to have these conversations."

"Effective and meaningful communication is one of the most important tools of good-quality medicine, especially when patients are dealing with challenging health issues. We believe that this intervention addresses this need for patients, and also supports clinicians by making it easier for them to have these conversations, through providing them with supportive tools to have what can often be very tough conversations," said Dr. Susan Block, founding chair of the Department of Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute; Professor of Psychiatry and Medicine at Harvard Medical School, and the palliative care specialist who led the creation of the Serious Illness Care Program at Ariadne Labs.

The centerpiece of the program is the Serious Illness Conversation Guide, developed by palliative care experts to enable clinicians and patients to gently and safely talk about the patient's prognosis and illness understanding, values and personal goals, fears and sources of strength, critical abilities that matter to their quality of life, and what they might be willing to go through for more time. Clinicians in the study received a 2.5 hour communication training with palliative care experts on how use the guide, followed by supportive coaching. The program also has patient and family conversation tools to prepare patients for conversations and support ongoing discussions with their family at home.

The program's system changes were designed to support clinicians in having the conversations, including routine identification of patients at high risk who would benefit from a serious illness conversation, reminders to have the conversation, and a template to document the conversation efficiently in the electronic medical record for the entire care team.

The program was tested with 91 doctors, nurse practitioners and physician assistants and 278 cancer patients at Dana Farber from September 2012 and June 2016. Half the patients took part in the Serious Illness Care program, while half in the control group received usual care.

No difference was found between the two groups in measures of goal-concordant care and peacefulness for patients who died. Researchers noted that these results reflect some of the study's limitations. The study had a smaller number of deaths than expected and fewer than expected survey responses from patients and families. Because of the limited sample size, researchers were unable to conclude whether the program was effective at improving these outcomes or if the outcome measures were appropriate.

"Our challenges reflect the urgent need in our field for patient-centered measures of communication that are agreed upon, validated, and demonstrably sensitive to communication interventions," study authors wrote.

To date, more than 13,500 clinicians have been trained to use the Serious Illness Conversation Guide and more than 300 organizations have implemented it. Ariadne Labs partners with health systems around the world to implement the program, including: Partners HealthCare and Brigham and Women's Hospital; Baylor, Scott & White Health in Texas; Penn Medicine; Lowell General PHO and Lahey Clinical Performance Network in partnership with BCBSMA.
"Effect of the Serious Illness Care Program in Outpatient Oncology," Rachelle Bernacki, MD, MS; Joanna Paladino, MD; Bridget A. Neville, MPH; Mathilde Hutchings; Jane Kavanagh, BA; Olaf P. Geerse BSc , Joshua Lakin, MD; Justin J. Sanders, MD, MSc; Kate Miller, PhD; Stuart Lipsitz, ScD; Atul A. Gawande, MD, MPH; Susan D. Block, MD. JAMA Internal Medicine, published online March 14, 2019, doi:10.1001/jamainternmed.2019.0077

"Evaluating an Intervention to Improve Communication Between Oncology Clinicians and Patients With Life-Limiting Cancer: A Cluster-Randomized Clinical Trial of the Serious Illness Care Program." Joanna Paladino, MD; Rachelle Bernacki, MD, MS; Bridget A. Neville, MPH; Jane Kavanagh, BA; Stephen P. Miranda, MD; Marissa Palmor, BS, MBE; Joshua Lakin, MD; Meghna Desai, MPH; Daniela Lamas, MD; Justin J. Sanders, MD, MSc; Jonathon Gass, MPH; Natalie Henrich, PhD, MPH; Stuart Lipsitz, ScD; Erik Fromme, MD; Atul A. Gawande, MD, MPH; Susan D. Block, MD. JAMA Oncology, published online March 14, 2019: doi:10.1001/jamaoncol.2019.0292

This study was supported by grants from the Branta Foundation, Charina Endowment Fund, Margaret T. Morris Foundation, Richard A. Cantor Fund, Partners HealthCare and the John A. Hartford Foundation.

Dana-Farber Cancer Institute

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...